1
BACKGROUND: Twenty-nine human platelet antigen systems have been described to date, but the majority of current genotyping methods are restricted to the identification of those most commonly associated with alloantibody production in a clinical context. This can result in a protracted investigation if causative human platelet antigens are rare or novel. A targeted nextgeneration sequencing approach was designed to detect all known human platelet antigens with the additional capability of identifying novel mutations in the encoding genes.
STUDY DESIGN AND METHODS:
A targeted enrichment, high-sensitivity HaloPlex assay was designed to sequence all exons and flanking regions of the six genes known to encode human platelet antigens. Indexed DNA libraries were prepared from 47 previously human platelet antigen-genotyped samples and subsequently combined into one of three pools for sequencing on an Illumina MiSeq platform. The generated FASTQ files were aligned and scrutinized for each human platelet antigen polymorphism using SureCall data analysis software.
RESULTS: Forty-six samples were successfully genotyped for human platelet antigens 1 through 29bw, with an average per base coverage depth of 1144. Concordance with historical human platelet antigen genotypes was 100%. A putative novel mutation in Exon 10 of the integrin b-3 (ITGB3) gene from an unsolved case of fetal neonatal alloimmune thrombocytopenia was also detected.
CONCLUSION:
A next-generation sequencing-based method that can accurately define all known human platelet antigen polymorphisms was developed. With the ability to sequence up to 96 samples simultaneously, our HaloPlex design could be used for high-throughput human platelet antigen genotyping. This method is also applicable for investigating fetal neonatal alloimmune thrombocytopenia when rare or novel human platelet antigens are suspected.
H uman platelet antigens (HPAs) are found on glycoproteins expressed on the surface of platelets. 1 Six genes code the 29 HPA systems currently described, and each HPA is characterized by a single nucleotide polymorphism (SNP) with the exception of HPA-14bw, which is defined by a threebase-pair deletion. 2 The discovery of HPA has often resulted from investigations of fetal and neonatal alloimmune thrombocytopenia (FNAIT) cases caused by antibodies and resulting in decreased platelet function and survival. 3 A range of molecular techniques has been employed to define the HPA systems, as reviewed by Nogu es in 2011. 4 The majority of HPA typing methods reported are restricted to defining those HPAs more commonly associated with FNAIT, but there is an argument for extending genotyping techniques to include all known HPAs due to increasing reports of maternal alloantibodies against "rare" HPAs. 5 To date, no published HPA genotyping method has reported the capacity to simultaneously detect all known HPA systems. Consequently, a two-tiered approach is often necessary when investigating the causative antigen of FNAIT, in particular when antibodies are against less common HPA systems or are produced as a result of a novel mutation, requiring full-length Sanger sequencing of one or more HPA-defining gene(s). 6, 7 In addition, methods that use sequence-specific primers or probes risk failure when polymorphic positions occur within binding sites. [8] [9] [10] Ideally, a single method capable of both detecting all known HPA SNPs and identifying novel mutations implicated in FNAIT should be employed. Next-generation sequencing (NGS) is a recent revolution in sequencing technology with the capacity to produce large amounts of sequence data relatively quickly and cheaply compared with Sanger sequencing methods. 11 Earlier this year, Lane and colleagues described the potential use of whole-genome sequencing by NGS for predicting red blood cell and platelet antigens. However, they indicated that a targeted NGS approach might be a more affordable option for laboratories, because, when combined with novel bar-coding technology, it can be used to sequence specific regions of the genome from many different individual samples in one pool.
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National Health Service Blood and Transplant maintains a panel of approximately 12,000 apheresis platelet donors for the management of alloimmune platelet-refractory patients, patients requiring intrauterine transfusion, and patients who should only be treated with single-donor platelets. Each new donor recruited is HPA typed on two separate occasions, resulting in the genotyping of around 5000 samples a year for HPA-1 through HPA-5 and HPA-15 using a high-throughput, real-time Taqman assay. 13 In addition, our laboratories routinely investigate cases of suspected FNAIT, primarily using polymerase chain reaction with sequencespecific primers (PCR-SSP) and sequencing-based typing technologies. In this study, we have designed a targeted NGS approach to define all known HPA systems in either patient or donor samples and assessed its capability for novel allele detection, particularly in cases of FNAIT due to rare or novel HPAs. These included duplicate DNA from three patients and archive material of mother and baby from an unresolved suspected case of FNAIT that had undergone sequencingbased typing.
MATERIALS AND METHODS

Historical HPA genotyping
All samples in this study had been previously genotyped for HPA-1 through HPA-5 and HPA-15 by TaqMan realtime PCR and or PCR-SSP, with some control DNA additionally tested for HPA-6bw and HPA-9bw by the same method. Several samples were also defined for HPA-7bw, HPA-8bw, HPA-10bw, HPA-11bw, HPA-27bw, and/or HPA28bw by either PCR-SSP or sequencing-based typing.
Assay design
To determine the feasibility of targeted NGS for HPA genotyping and assess whether our NGS approach would also be clinically useful to detect novel HPAs, we designed a panel of probes to detect the six genes known to encode HPA, capturing all exons and flanking regions. A custom HaloPlex high-sensitivity (HS) panel (Agilent Technologies) was created using Agilent's online SureDesign HaloPlex advanced design wizard. Designs were based on hg19 GRCh37 references sequences, with target sources obtained from the RefSeq database. Targets comprised all coding exons plus 50 nucleotides of the respective 5 0 and 3 0 flanking intronic sequences for integrin b-3 (ITGB3), ITGA2B, ITGA2, glycoprotein Ib platelet a subunit (GP1BA), glycoprotein Ib platelet b subunit (GP1BB), and cluster of differentiation 9 (CD109) genes. An additional probe group designed with reduced stringency was required for two regions of ITGB3 and ITGA2B due to low coverage, although neither region encoded known HPA SNPs. In total, 1241 amplicons were created, with predicted 100% coverage of 108 target regions covering 27,084 kb (Table 1) .
Targeted enrichment and sequencing
Indexed DNA libraries were prepared from 50 ng genomic DNA (1.8 ng/mL for each sample) using the bespoke HaloPlexHS target-enrichment assay for Illumina sequencing (Agilent Technologies) following the manufacturer's instructions. Briefly, each sample of genomic DNA was digested with a standard panel of 16 restriction enzymes, in the form of eight double digests, for 30 minutes at 378C. Digested DNA was then hybridized to the custom HaloPlexHS probe library and indexing primers for 2 hours at 588C. After removal from the hybridization buffer with AMPure XP beads (Beckman Coulter), the circularized fragments were ligated, captured with streptavidinlabeled Dynabeads (ThermoFisher Scientific), and amplified using the following PCR program: 988C for 2 minutes; 25 cycles at 988C for 30 seconds, at 608C for 30 seconds, and at 728C for 1 minute; 728C for 10 minutes; and held at 88C. PCR products were subsequently purified with AMPure XP beads and evaluated with a Bioanalyzer 2100 (Agilent Technologies) or quantified using a Qubit (ThermoFisher Scientific). DNA libraries prepared from external qualityassessment samples, patient samples, and control DNA were combined into one of three pools, respectively, for downstream sequencing. Equimolar pooling was used for the first experiment, but subsequent pooling was based on equal volumes of each sample to minimize cost and time. Each pooled library was validated with a Bioanalyzer 2100 to assess fragment size and concentration and then normalized to approximately 4 nM. Based on the Illumina MiSeq System Denature and Dilute Libraries Guide, 10 pM of the pooled library was then loaded onto an MiSeq (Illumina) for 2 3 151 paired-end sequencing using either a Nano or Standard v2 cartridge and flow cell ( Table 2 ). The MiSeq Reporter software (Illumina) settings were adjusted to generate FASTQ files for index reads.
Data analysis
Primary data analysis was performed using MiSeq Reporter to generate a pair of FASTQ files for each sample. FASTQ files generated were then analyzed using SureCall NGS data analysis software version 3.0.3.1 (Agilent Technologies) using the pipelines described below.
HPA genotyping
Single-sample analysis was performed using the default HaloPlex method, and chromosomal positions were scrutinized using triage view for the respective positions for each HPA system. The nucleotides observed were used to manually assign genotypes for HPA-1 through HPA-29bw, in accordance with data available from the Immuno Polymorphism Database (IPD-HPA).
2 All HPA genotypes generated by NGS were then compared with those HPA systems previously defined in each sample, and concordance was determined.
Novel mutation detection
FASTQ files from the suspected FNAIT case were analyzed using HaloPlex default for pair analysis (Tumor Normal Method). Nucleotide differences determined between mother and baby for the six genes sequenced were subsequently scrutinized for their potential to be implicated in FNAIT.
RESULTS
HPA genotyping
Forty-six samples were successfully genotyped for HPA-1 through HPA-29bw, with one sample excluded because of possible contamination. All HPA genotypes produced were 100% concordant with historical data. Because of the rarity of many HPA genotypes, not all potential combinations were tested in this cohort. The majority of HPA systems were homozygous for the more common "a" allele observed in the UK population. However, both "a" and "b" alleles were represented in one or more samples for HPA-1 through HPA-7bw, HPA-9bw, HPA-5, HPA-27bw, and HPA-28bw (Fig. 1) . Sequence quality
The quality parameters of each sequence obtained by our HaloPlexHS method were scrutinized to verify the accuracy of each HPA genotype assigned.
Sequencing coverage
Cluster density on the flow cell was similar for each MiSeq run performed, ranging from 1115 to 1226 K per mm 2 , with greater than 87% of clusters passing the filter on each occasion. On average, a per-base depth of coverage (DoC) of 11443 was obtained for each sample, although the mean value varied between the three HaloPlex experiments performed, with an average of 5843, 15823, and 9783, respectively. Variability in the depth of coverage between samples was minimal in the first experiment but was wider in subsequent experiments (Fig. 2) .
Coverage per HPA system
The highest average per-base DoC was obtained for HPA23bw, with 26153 (range, 469-5849), and the HPA system with the lowest average DoC per base was HPA-20bw, with 3353 (range, 18-664). Although the average depth observed for each HPA SNP did vary between each MiSeq run, the variability in coverage between each HPA appeared to be consistent (Fig. 3) .
Allele balance
In all heterozygous samples, the ratio of sequence depth obtained for individual SNPs was even, with a mean of 51% for allele "a" and 49% for allele "b," ranging from 41 to 60% and 40 to 50%, respectively. Those HPAs with fewer heterozygous examples in our cohort tended to have slightly uneven allele balance.
FNAIT investigation
In addition to determining the full HPA genotype for both mother (AB) and baby (BB) from the unsolved, suspected FNAIT case, all coding regions of the six genes sequenced were examined using SureCall pair analysis.
Novel mutation detection
The HaloPlex Tumor Normal method with AB as the reference indicated 10 mutations of interest, in which AB was homozygous but BB was heterozygous ( Table 3) . Five of the mutations were noncoding and thus were excluded. Another three were previously reported SNPs but with no association to FNAIT (National Center for Biotechnology Information SNP Database). HPA-15 was potentially clinically significant, with the mother typing as HPA-15aa and the baby determined to be HPA-15ab. However, this HPA system had been previously excluded by the laboratory as causative of FNAIT in the original investigation. The remaining difference between mother and baby indicated a novel SNP in the ITGB3 gene (c.1373A> G, p.Asp458Gly) present in the baby's sample. Although there was insufficient DNA to sequence the historical paternal sample, look back of original Sanger sequencing data was able to confirm inheritance of this mutation in BB (data not shown).
DISCUSSION
To our knowledge, this is the first reported NGS-based approach to define all known HPAs concurrently in a targeted genotyping assay. To determine the feasibility of using targeted NGS for HPA genotyping, we designed a panel of HaloPlexHS probes to detect the six genes that encode all currently defined HPA systems. However, rather than simply targeting regions that contained known HPA SNPs, probe groups were designed to capture all exons and flanking regions to assess whether our NGS approach might also be clinically useful for investigating FNAIT.
The flow cell cluster density and the percentage of clusters passing the filter observed for each MiSeq run indicated that an optimal amount of library had been loaded, based on recommended values.
14 Per-base DoC is a key quality parameter for NGS to ensure reliable base calling and subsequent alignment to the reference genome by analysis software. Although there is no consensus for a minimum DoC required, it is generally accepted that average depth in excess of 303 is acceptable for the detection of SNPs, 15 and a recent study demonstrated that the accuracy of sequencing actually improves once the read depth goes beyond 103. 16 All HaloPlex experiments produced a mean DoC well above this minimum acceptable level. However, the data generated by each MiSeq run were quite disparate. Substantial variability in the mean DoC for each HPA SNP was consistently observed. One factor that might have influenced coverage is the GC content of each region sequenced. Sequences with a higher proportion of G and C nucleotides are reportedly less likely to denature during PCR, 17 which may have affected the efficiency of the enrichment stage of the HaloPlexHS protocol. Indeed, Exon 20 of the ITGA2B gene, which encodes HPA-20bw, exhibited the lowest mean coverage and has a GC content of 66% compared with the 48% GC content of Exon 12 of the ITGB3 gene, which encodes HPA-23bw, the SNP with the highest observed DoC in each experiment. Overall, the Fisher exact test indicates a significant association between the mean DoC for each HPA SNP and the GC content of the respective encoding exon (p 5 0.0317). Variability of the overall mean DoC observed between experiments might be explained by differences in samples numbers, the MiSeq cartridge used, and the amount of Pooled Amplicon Library loaded for each run. However, the wider range of coverage depth seen in the second and third experiments is more likely explained by the method of pooling employed. Samples in the first experiment were pooled in equimolar amounts. Excluding an outlier sample (which was at a very low concentration), the variability of DoC between samples in this first HaloPlex run was minimal, ranging from just 539 to 775 base pairs compared with a range of 185 to 775 base pairs observed in the 11 samples overall. This range of coverage depth increased considerably in subsequent experiments when samples were pooled by equal volume. To pool at equimolar concentration, the Bioanalyzer 2100 was required to determine the molarity of each library. Although use of the Bioanalyzer allows scrutiny of each individual library, equimolar pooling is both costly and time consuming compared with pooling in equal volumes. 18 This is particularly the case for experiments containing more than 11 samples due to the limited number of libraries that can be loaded onto a single Bioanalyzer chip. An alternative approach might be to estimate the molarity, because all libraries should be a similar composition due to AMPure bead size selection. This is likely to produce results similar to those observed using equimolar pooling without the additional cost of individual library assessment using a Bioanalyzer. Lack of coverage uniformity across regions using the HaloPlex target enrichment system has been previously reported by others. [19] [20] [21] The impact of uneven coverage can be minimized by ensuring that the DoC reaches the required minimum for the regions with the lowest coverage, although this may limit the number of samples that can be multiplexed. Reducing variability between samples will allow a better estimate of the maximum number of samples that can be pooled and still maintain the deep sequencing required to produce accurate SNP detection. In addition to the DoC, the accuracy of bases calls for heterozygous SNPs depends on allele balance, with errors increasing as the ratio of alleles falls below 20:80. 16 The allele balance observed for all heterozygous HPAs within our cohort was well within this acceptable range. Although heterozygous samples were not available for all HPA systems, the evenness in allele balance observed with those sequenced suggests that rarer HPAs would be detected. All samples that were successfully genotyped for HPS using our HaloPlexHS target-enrichment assay produced 100% concordant genotypes with historical data originally defined using a variety of molecular techniques. Although it was not possible to test all permutations of HPA using HaloPlex due to the rarity of some genotypes, the results obtained provide convincing evidence that a targeted NGS approach is a viable option for simultaneously HPA typing both patient and donor samples for all known HPA systems within a matter of days.
An advantage of an NGS-based approach over Sanger sequence-based HPA typing is that only a small amount of input DNA is required. 22 This is particularly important for clinical investigations, where patient material may be very limited due to neutropenia, or in the case of a neonate. Another benefit of this approach is that NGS should not be adversely affected by rare SNPs that have been known to affect the accuracy of some conventional PCRbased HPA genotyping techniques. 23 In this report, up to 21 samples were HPA typed simultaneously. However, current index combinations provided in the HaloPlexHS assay allow for up to 96 samples to be sequenced in a single experiment. It is anticipated that the optimization of sample pooling in particular will increase the capacity to multiplex, although the actual number of DNA libraries that can be combined without compromising overall sequence quality has to be determined. HaloPlexHS has the potential for automation, which would be beneficial if used for high-throughput HPA genotyping to maintain accuracy and consistency and to minimize hands-on time. A higher throughput of samples would also require some development of the data analysis pipeline to rationalize the scrutiny of sequences, the assignment of HPA genotypes, and the production of clinical reports.
Included in the sample cohort was DNA from a mother and her baby from an historical but unsolved FNAIT case. By comparing differences in the six genes sequenced, a putative novel HPA allele was identified (c.1373A>G), resulting in an amino acid change from aspartic acid to glycine. The location of this novel mutation in Exon 10 of the ITGB3 gene, a region that also encodes HPA-6bw and HPA-7bw, suggests that this novel mutation may have clinical significance and could be implicated in FNAIT. This is currently the subject of further investigation.
For laboratories that have access to an MiSeq platform, targeted NGS is a viable option for both donor and patient HPA genotyping. For a high-throughput workflow typing 96 samples, targeted NGS reagent costs are currently within 20% of the Bioarray. For typing a low number of samples, there is a similar price differential between targeted NGS and the Fluogene system. However, because our targeted NGS approach defines all 29 HPA systems versus only 11 systems with the Bioarray and seven with Fluogene, the cost per HPA is significantly cheaper with targeted NGS.
